IL-27 Enhances the Expression of TRAIL and TLR3 in Human Melanomas and Inhibits Their Tumor Growth in Cooperation with a TLR3 Agonist Poly(I:C) Partly in a TRAIL-Dependent Manner
Figure 5
IL-27 and poly(I:C) cooperatively inhibit in vivo tumor growth of human melanoma in immunodeficient mice.
Immunodeficient NOD/SCID mice were s.c. injected with human melanoma cells of the SK-MEL-37 cell line, and treated by weekly i.v. injections with PBS alone, IL-27 (1 µg), poly(I:C) (30 µg), or IL-27 (1 µg) plus poly(I:C) (30 µg) from 1 week postengraftment. Tumor growth was monitored weekly and expressed as volume (mm3). Data are shown as means ± SD. * indicates p < 0.05, compared with PBS. Similar results were obtained in two independent experiments.